This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1994 Nov;1(1):2-3.

Gene therapy: hopes, hypes, and hurdles

I M Verma¹

Affiliations

PMID: 8790596
PMCID: PMC2229927

Gene therapy: hopes, hypes, and hurdles

I M Verma. Mol Med. 1994 Nov.

. 1994 Nov;1(1):2-3.

Author

I M Verma¹

Affiliation

¹ Molecular Biology and Virology Laboratory, Salk Institute, La Jolla, California, USA.

PMID: 8790596
PMCID: PMC2229927

No abstract available

PubMed Disclaimer

Similar articles

Commentary: an aye for eye gene therapy.
Bennett J. Bennett J. Hum Gene Ther. 2006 Feb;17(2):177-9. doi: 10.1089/hum.2006.17.177. Hum Gene Ther. 2006. PMID: 16454651 No abstract available.
Gendicine: the first commercial gene therapy product.
Wilson JM. Wilson JM. Hum Gene Ther. 2005 Sep;16(9):1014-5. doi: 10.1089/hum.2005.16.1014. Hum Gene Ther. 2005. PMID: 16149899 Chinese, English. No abstract available.
Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.
Peng Z. Peng Z. Hum Gene Ther. 2005 Sep;16(9):1016-27. doi: 10.1089/hum.2005.16.1016. Hum Gene Ther. 2005. PMID: 16149900 Review. No abstract available.
Gene therapy's out-of-body experience.
Scott CT, DeFrancesco L. Scott CT, et al. Nat Biotechnol. 2016 Jun 9;34(6):600-7. doi: 10.1038/nbt.3592. Nat Biotechnol. 2016. PMID: 27281416 No abstract available.
[Gene therapy and rare diseases].
Cohen-Haguenauer O. Cohen-Haguenauer O. Rev Med Interne. 2011 Dec;32 Suppl 2:S210-2. doi: 10.1016/j.revmed.2011.09.015. Epub 2011 Oct 28. Rev Med Interne. 2011. PMID: 22037347 Review. French. No abstract available.

See all similar articles

Cited by

An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication.
An DS, Morizono K, Li QX, Mao SH, Lu S, Chen IS. An DS, et al. J Virol. 1999 Sep;73(9):7671-7. doi: 10.1128/JVI.73.9.7671-7677.1999. J Virol. 1999. PMID: 10438857 Free PMC article.
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Unutmaz D, et al. J Exp Med. 1999 Jun 7;189(11):1735-46. doi: 10.1084/jem.189.11.1735. J Exp Med. 1999. PMID: 10359577 Free PMC article.
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases.
Lin C, Greenblatt MB, Gao G, Shim JH. Lin C, et al. Hum Gene Ther. 2024 May;35(9-10):317-328. doi: 10.1089/hum.2024.022. Epub 2024 Apr 8. Hum Gene Ther. 2024. PMID: 38534217 Review.
High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells.
An DS, Koyanagi Y, Zhao JQ, Akkina R, Bristol G, Yamamoto N, Zack JA, Chen IS. An DS, et al. J Virol. 1997 Feb;71(2):1397-404. doi: 10.1128/JVI.71.2.1397-1404.1997. J Virol. 1997. PMID: 8995665 Free PMC article.
Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals.
Barar J, Omidi Y. Barar J, et al. Bioimpacts. 2013;3(3):105-9. doi: 10.5681/bi.2013.028. Epub 2013 Sep 17. Bioimpacts. 2013. PMID: 24163801 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information